<DOC>
	<DOCNO>NCT02073500</DOCNO>
	<brief_summary>The aim study identify biomarkers disease recurrence prognosis optimize patient selection treatment cytoreductive surgery ( CRS ) hyperthermic intraperitoneal chemotherapy ( HIPEC ) , animal model explore different treatment strategy peritoneal surface malignancy ( PSM ) .</brief_summary>
	<brief_title>Peritoneal Surface Malignancies - Characterization , Models Treatment Strategies</brief_title>
	<detailed_description>The handling patient PSM involve multimodal multidisciplinary treatment strategy CRS , removal macroscopically detectable tumor , HIPEC , instillation heat chemotherapy abdominal cavity remove residual cancer disease . The treatment challenge complex associate significant morbidity . Only patient limited disease benefit treatment , good method patient selection need . The project group unique opportunity address key question acquire experience , exceptional biobank institutional database novel animal model establish Norwegian Radium Hospital .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pseudomyxoma Peritonei</mesh_term>
	<criteria>age &gt; 18 year confirm diagnosis peritoneal surface malignancy candidate CRSHIPEC write informed consent Approximately 80 patient per year eligible inclusion , number patient annually receive surgical treatment PSM .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Peritoneal carcinomatosis</keyword>
	<keyword>Peritoneal surface malignancy</keyword>
	<keyword>Cytoreductive surgery</keyword>
	<keyword>Hyperthermic intraperitoneal chemotherapy</keyword>
	<keyword>CRS</keyword>
	<keyword>HIPEC</keyword>
	<keyword>Prognostic biomarker</keyword>
	<keyword>Predictive biomarker</keyword>
</DOC>